Neuron-specific differentially methylated regions in cell-free DNA (Neuron-specific cfDNA DMRs)

Neuron-specific differentially methylated regions (DMRs) in cell-free DNA (cfDNA) are epigenetic signatures used as highly specific biomarkers for detecting neuronal injury and neurodegeneration (Moss et al., 2018, Nature Communications). These regions are characterized by unique DNA methylation patterns—typically hypomethylation or hypermethylation at specific CpG sites—that distinguish neurons from other cell types in the body (Lehmann-Werman et al., 2016, PNAS). When neurons undergo cell death via apoptosis or necrosis, their genomic DNA is fragmented and released into the systemic circulation, where it can be detected via liquid biopsy (Cheng et al., 2023, Frontiers in Genetics). By quantifying these brain-derived cfDNA fragments, researchers can non-invasively monitor the progression of diseases such as Alzheimer's, Parkinson's, and traumatic brain injury. Unlike protein biomarkers, which may be subject to rapid clearance or lack tissue specificity, DNA methylation provides a stable and cell-type-specific fingerprint of the cell of origin. This technology enables the assessment of real-time tissue damage and the evaluation of neuroprotective drug efficacy in clinical trials. Currently, these DMRs are utilized as diagnostic and prognostic tools rather than direct therapeutic targets.

Other names

Brain-derived cell-free DNANeuron-specific methylation markersNeuro-specific DMRsCirculating brain-derived DNANeuronal epigenetic biomarkers